Decheng Capital’s Lyell Immunopharma LYEL Stock Holding History

Decheng Capital’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.9M	Hold	692,050	–	–	2.1%	6
2025 Q4	$21.3M	Buy	692,050 +96,584	+16%	+$2.16M	2.87%	5
2025 Q3	$9.67M	Hold	595,466	–	–	1.69%	8
2025 Q2	$5.26M	Sell	595,466 -1	-0%	-$9	1.33%	12
2025 Q1	$6.41M	Hold	595,467	–	–	1.8%	11
2024 Q4	$7.62M	Buy	+595,467	New	+$11.8M	1.63%	13

Other funds holding LYEL

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

GSK plc London $599M AUM

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return